Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the potential benefit of adding Digoxin to
erlotinib (Tarceva) treatment for patients with non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
James Graham Brown Cancer Center University of Louisville
Collaborators:
James Graham Brown Cancer Center University of Louisville